.svg){kind=small}
The study comprised a total of 232 randomised males and it measured, as its primary endpoint, improvement in the erectile function ("EF") domain score of the International Index of Erectile Function ("IIEF"), the scoring system used for the approval of PDE5 inhibitors such as Viagra®. The study was of a placebo-controlled, double blind, home use, crossover design.View news article
.avif)
Latest news
Richmond Pharmacology Welcomes Back Dr Edward Jackson as Medical Director
November 3, 2025
Richmond Pharmacology is pleased to announce the return of Dr Edward Jackson, who re-joins the organisation as Medical Director.
Read moreEvents
JSCPT 2025
5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event
